Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole Mayer-Hamblett

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
The Lancet. Respiratory Medicine|January 17, 2014
Acute antibiotic use in cystic fibrosis clinical trials: does it affect our assessment of clinical efficacy?Nicole Mayer-Hamblett, Felix Ratjen
Current Opinion in Pulmonary Medicine|July 15, 2017
Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapiesDonald R VanDevanter, Nicole Mayer-Hamblett
Contemporary Clinical Trials|April 20, 2005
Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial settingNicole Mayer-Hamblett, Richard A Kronmal
American Journal of Respiratory and Critical Care Medicine|November 19, 2013
The yin and yang of indoor airborne exposures to endotoxinChristopher H Goss, Nicole Mayer-Hamblett
Thorax|February 24, 2016
Advancing clinical development pathways for new CFTR modulators in cystic fibrosisNicole Mayer-Hamblett, Michael Boyle, Donald VanDevanter
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 14, 2019
Expanding access to CFTR modulators for rare mutations: The utility of n-of-1 trialsAmalia S Magaret, Nicole Mayer-Hamblett, Donald VanDevanter
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 13, 2017
Feasibility of placebo-controlled trial designs for new CFTR modulator evaluationDonald R VanDevanter, Nicole Mayer-Hamblett, Michael Boyle
Journal of Biopharmaceutical Statistics|May 13, 2026
Special issue: cell and gene causal inference in the design and analysis of gene therapy clinical trialsDebashis Ghosh, Nicole Mayer-Hamblett, Alexander M Kaizer
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 8, 2013
Evaluating the predictive ability of sweat chlorideSonya L Heltshe, Steven M Rowe, Nicole Mayer-Hamblett
The Lancet. Respiratory Medicine|June 15, 2023
Reducing treatment burden in the era of CFTR modulators - Authors' replyAlex H Gifford, Nicole Mayer-Hamblett, David P Nichols
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
The Lancet. Respiratory Medicine|January 17, 2014
Acute antibiotic use in cystic fibrosis clinical trials: does it affect our assessment of clinical efficacy?Nicole Mayer-Hamblett, Felix Ratjen
Current Opinion in Pulmonary Medicine|July 15, 2017
Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapiesDonald R VanDevanter, Nicole Mayer-Hamblett
Contemporary Clinical Trials|April 20, 2005
Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial settingNicole Mayer-Hamblett, Richard A Kronmal
American Journal of Respiratory and Critical Care Medicine|November 19, 2013
The yin and yang of indoor airborne exposures to endotoxinChristopher H Goss, Nicole Mayer-Hamblett
Thorax|February 24, 2016
Advancing clinical development pathways for new CFTR modulators in cystic fibrosisNicole Mayer-Hamblett, Michael Boyle, Donald VanDevanter
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 14, 2019
Expanding access to CFTR modulators for rare mutations: The utility of n-of-1 trialsAmalia S Magaret, Nicole Mayer-Hamblett, Donald VanDevanter
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 13, 2017
Feasibility of placebo-controlled trial designs for new CFTR modulator evaluationDonald R VanDevanter, Nicole Mayer-Hamblett, Michael Boyle
Journal of Biopharmaceutical Statistics|May 13, 2026
Special issue: cell and gene causal inference in the design and analysis of gene therapy clinical trialsDebashis Ghosh, Nicole Mayer-Hamblett, Alexander M Kaizer
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 8, 2013
Evaluating the predictive ability of sweat chlorideSonya L Heltshe, Steven M Rowe, Nicole Mayer-Hamblett
The Lancet. Respiratory Medicine|June 15, 2023
Reducing treatment burden in the era of CFTR modulators - Authors' replyAlex H Gifford, Nicole Mayer-Hamblett, David P Nichols
Pageof 14